QTTB — Q32 Bio Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1661998 ·
Last close
$7.09
Market Cap
$120.22M
52W High
$8.05
52W Low
$4.17
ADV30
310,717
Next earnings
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -7,722,000 -7,609,000 63,675,000 50,751,000 17,362,000
Dec 2025 53,737,000 45,879,000 57,730,000 61,776,000 48,297,000 19,762,000
Sep 2025 0 -7,577,000 -7,389,000 57,784,000 49,039,000 76,232,000
Jun 2025 0 -9,171,000 -9,489,000 66,117,000 54,832,000 78,352,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-33,543,000
Investing CF
$7,000,000
Financing CF
$-3,125,000
CapEx
$-60,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-3.74
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-204,993,000
Inventory
Receivables
$5,392,000
ST Investments
EBIT TTM
$30,921,000
Pretax Income TTM
$29,821,000
Interest Exp TTM
$1,100,000
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$53,737,000
EBITDA
$21,770,000
Free Cash Flow
$9,871,000
Enterprise Value
$61,242,208
Total Cash
$50,751,000
Total Debt
$13,646,000
Shares Out
16,956,415
Trailing EPS
$2.78
Book Value
$3.17
ROE
157.2%
ROA
18.7%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 53,737,000 16,902,000 29,821,000 61,776,000 19,762,000 -33,543,000
Dec 2024 0 -66,102,000 -47,733,000 92,332,000 86,657,000 -67,715,000
Dec 2023 -6,651,000 -48,255,000 -53,743,000 47,057,000 229,978,000 -18,677,000
Dec 2022 6,651,000 -39,225,000 -42,809,000 61,774,000 192,486,000 -10,957,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-5.36

Peers — same industry

TickerNameMarket CapLastDaily %
PLYX Polaryx Therapeutics, Inc. $122.15M $2.58
HSTC HST Global, Inc. $117.39M $0.83
CYPH CYPHERPUNK TECHNOLOGIES INC. $123.50M $1.16
INDP Indaptus Therapeutics, Inc. $125.70M $1.11
VTVT vTv Therapeutics Inc. $130.61M $33.16

News headlines (Yahoo Finance, 1h cache)

Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 145.69%: Read This Before Placing a Bet
2026-05-26 13:55 · Yahoo
Wall Street Analysts Believe Q32 Bio (QTTB) Could Rally 163.42%: Here's is How to Trade
2026-05-08 13:55 · Yahoo
Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-05 10:59 · Yahoo
Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?
2026-04-30 19:10 · Yahoo
Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference
2026-04-08 10:59 · Yahoo
Does Q32 Bio (QTTB) Have the Potential to Rally 97.66% as Wall Street Analysts Expect?
2026-03-30 13:55 · Yahoo
Best Momentum Stocks to Buy for March 27th
2026-03-27 14:15 · Yahoo
New Strong Buy Stocks for March 27th
2026-03-27 08:35 · Yahoo
Q32 Bio (QTTB) Upgraded to Strong Buy: Here's What You Should Know
2026-03-19 16:00 · Yahoo
Best Momentum Stocks to Buy for March 19th
2026-03-19 14:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.